A multicenter, single-arm, open-label expanded access program for lenalidomide plus dexamethasone in previously treated subjects with multiple myeloma.

Trial Profile

A multicenter, single-arm, open-label expanded access program for lenalidomide plus dexamethasone in previously treated subjects with multiple myeloma.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 02 Aug 2011 New source identified and integrated (European Clinical Trials Database).
    • 20 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Actual patient number (150) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top